{
    "clinical_study": {
        "@rank": "80772", 
        "arm_group": [
            {
                "arm_group_label": "Ertugliflozin 15 mg - Moderate Hepatic Impairment", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive a single 15 mg oral dose of ertugliflozin"
            }, 
            {
                "arm_group_label": "Ertugliflozin 15 mg - Healthy Participants", 
                "arm_group_type": "Other", 
                "description": "Participants receive a single 15 mg oral dose of ertugliflozin"
            }, 
            {
                "arm_group_label": "Ertugliflozin 15 mg - Mild Hepatic Impairment", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive a single 15 mg oral dose of ertugliflozin"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study to assess the pharmacokinetics and safety of ertugliflozin (MK-8835,\n      PF-04971729) in participants with hepatic impairment versus healthy participants.  In Part 1\n      of the study, participants with moderate hepatic impairment (Child-Pugh score 7-9) and\n      matched healthy participants will be enrolled; depending on results in Part 1, Part 2 may be\n      conducted and will enroll participants with mild hepatic impairment (Child-Pugh score 5-6)."
        }, 
        "brief_title": "Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        ALL PARTICIPANTS:\n\n          -  Body Mass Index (BMI) of 18 to 40 kg/m^2; and a total body weight >50 kg (110 lbs)\n\n          -  Male or female not of reproductive potential\n\n          -  If a female of reproductive potential, agrees to remain abstinent from heterosexual\n             activity or agree to use or have their partner use 2 methods of acceptable\n             contraception to prevent pregnancy while the participant is receiving study\n             medication and for 14 days after the last dose of study medication PARTICIPANTS WITH\n             NORMAL HEPATIC FUNCTION\n\n          -  Healthy with normal hepatic function PARTICIPANTS WITH HEPATIC IMPAIRMENT\n\n          -  Satisfy the criteria for Child-Pugh classification [moderate (Part 1): Child-Pugh\n             Scores 7-9 points, mild (Part 2): Child-Pugh Scores 5-6 points] within 14 days before\n             administration of study medication\n\n          -  A diagnosis of hepatic impairment due to primary liver disease and not secondary to\n             other diseases\n\n          -  Stable hepatic impairment, defined as no clinically-significant change in disease\n             status within the last 30 days\n\n          -  On a stable dose of medication and/or treatment regimen used to manage hepatic\n             disease for at least 4 weeks prior to study start\n\n        Exclusion Criteria:\n\n          -  ALL PARTICIPANTS\n\n          -  A known hypersensitivity or intolerance to ertugliflozin or any other Sodium-Glucose\n             co-Transporter 2 (SGLT2) inhibitor (i.e., canagliflozin [Invokana], dapagliflozin\n             [Farxiga], empagliflozin, or ipragliflozin)\n\n          -  Febrile illness within 5 days prior to the first dose of study medication\n\n          -  Any clinically significant malabsorption condition\n\n          -  A positive urine drug screen for drugs of abuse or recreational drugs\n\n          -  Abuse of alcohol or binge drinking and/or any other illicit drug use or dependence\n             within 6 months of study start\n\n          -  Treatment with an investigational drug within 30 days preceding the first dose of\n             study medication\n\n          -  Pregnant or breastfeeding females\n\n          -  Use of herbal supplements within 28 days prior to the first dose of study medication\n\n          -  Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more\n             within 56 days prior to dosing\n\n          -  History of sensitivity to heparin or heparin-induced thrombocytopenia\n\n          -  PARTICIPANTS WITH NORMAL HEPATIC FUNCTION\n\n          -  Use of prescription drugs (hormonal methods of birth control are allowed), vitamins,\n             and dietary supplements within 7 days prior to the first dose of study medication\n\n          -  Positive serology for Hepatitis B or C\n\n          -  PARTICIPANTS WITH HEPATIC IMPAIRMENT\n\n          -  Hepatic carcinoma and hepatorenal syndrome or life expectancy less than 1 year\n\n          -  Undergone portal-caval shunt surgery\n\n          -  History of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers\n             less than one month prior to study entry\n\n          -  Signs of significant hepatic encephalopathy\n\n          -  Severe ascites and/or pleural effusion\n\n          -  A transplanted kidney, heart or liver\n\n          -  Received any of the following medications within 7 days prior to the first dose of\n             study medication or during the study: Other SGLT2 inhibitors (eg, dapagliflozin,\n             canagliflozin, empagliflozin, and ipragliflozin); Any potent drug-metabolizing\n             enzyme-inducing drug, including rifampin, phenytoin, and carbamazepine; Probenecid,\n             valproic acid, gemfibrozil"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02115347", 
            "org_study_id": "8835-014"
        }, 
        "intervention": {
            "arm_group_label": [
                "Ertugliflozin 15 mg - Moderate Hepatic Impairment", 
                "Ertugliflozin 15 mg - Healthy Participants", 
                "Ertugliflozin 15 mg - Mild Hepatic Impairment"
            ], 
            "intervention_name": "Ertugliflozin 15 mg", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 2, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Non-randomized, Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Subjects With Hepatic Impairment and the Healthy Subjects With Normal Hepatic Function", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck/Pfizer", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration (AUClast) for ertugliflozin", 
                "safety_issue": "No", 
                "time_frame": "Hour 0 (predose), and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours"
            }, 
            {
                "measure": "AUC from Hour 0 to infinity (AUCinf) for ertugliflozin", 
                "safety_issue": "No", 
                "time_frame": "Hour 0 (predose), and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02115347"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "AUClast for fraction of ertugliflozin unbound in plasma (AUClast,u)", 
                "safety_issue": "No", 
                "time_frame": "Hour 0 (predose), and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours"
            }, 
            {
                "measure": "AUCinf for fraction of ertugliflozin unbound in plasma (AUCinf,u)", 
                "safety_issue": "No", 
                "time_frame": "Hour 0 (predose), and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours"
            }, 
            {
                "measure": "Maximum plasma concentration (Cmax) of ertugliflozin", 
                "safety_issue": "No", 
                "time_frame": "Hour 0 (predose), and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours"
            }, 
            {
                "measure": "Cmax for fraction of ertugliflozin unbound in plasma (Cmax,u)", 
                "safety_issue": "No", 
                "time_frame": "Hour 0 (predose), and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours"
            }, 
            {
                "measure": "Number of participants who experienced an adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 19 days"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}